49. Systemic lupus erythematosus
827 clinical trials,   638 drugs   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-000705-59-DE
(EUCTR)
11/04/200607/06/2005A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE FlaresA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE Flares Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
Other descriptive name: hLL2 (trivial name or chemical description)
UCB Pharma, IncNULLNot RecruitingFemale: yes
Male: yes
510Phase 3Hungary;United Kingdom;Germany;Spain;Italy
2EUCTR2005-000705-59-HU
(EUCTR)
09/01/200612/10/2005A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE FlaresA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE Flares Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
Other descriptive name: hLL2 (trivial name or chemical description)
Immunomedics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
510Phase 3Hungary;Germany;United Kingdom;Spain;Italy
3EUCTR2005-000706-31-DE
(EUCTR)
05/01/200628/06/2005A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLEA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
Other descriptive name: hLL2 (trivial name or chemical description)
UCB Pharma Inc.NULLNot RecruitingFemale: yes
Male: yes
300Phase 3United Kingdom;Germany;Spain;Italy
4EUCTR2005-000705-59-SK
(EUCTR)
14/10/200529/07/2005A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE FlaresA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems. - Phase III Study of Epratuzumab in Severe Acute SLE Flares Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
Other descriptive name: hLL2 (trivial name or chemical description)
Immunomedics, Inc.NULLNot RecruitingFemale: yes
Male: yes
510Phase 3Hungary;Slovakia;Spain;Germany;Italy;United Kingdom
5EUCTR2005-000706-31-ES
(EUCTR)
25/07/200523/05/2006A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLEA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
INN or Proposed INN: Epratuzumab
Other descriptive name: hLL2 (trivial name or chemical description)
Immunomedics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 3Germany;United Kingdom;Spain;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2005-000706-31-BE
(EUCTR)
29/06/200526/07/2005A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLEA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
Other descriptive name: hLL2 (trivial name or chemical description)
UCB Pharma Inc.NULLNot RecruitingFemale: yes
Male: yes
300Phase 3Spain;Belgium;Germany;Italy;United Kingdom
7EUCTR2005-000705-59-GB
(EUCTR)
07/06/200519/04/2005A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE FlaresA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurological Systems - Phase III Study of Epratuzumab in Severe Acute SLE Flares Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
Other descriptive name: hLL2 (trivial name or chemical description)
Immunomedics, Inc.NULLNot RecruitingFemale: yes
Male: yes
510Phase 3Hungary;Germany;United Kingdom;Spain;Italy
8EUCTR2005-000706-31-GB
(EUCTR)
13/05/200519/04/2005A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLEA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus - Phase III Study of Epratuzumab in Active SLE Systemic Lupus Erythematosus
Classification code 10042945
Product Name: Epratuzumab
Product Code: IMMU-103
Other descriptive name: hLL2 (trivial name or chemical description)
Immunomedics, Inc.NULLNot RecruitingFemale: yes
Male: yes
300Phase 3Germany;United Kingdom;Spain;Italy